Udhayvir S. Grewal, MD, on DLL3-Targeting Agents: T-Cell Engagers and Beyond
Udhayvir S. Grewal, MD, of Emory Winship Cancer Institute, reviews emerging therapeutic approaches and ongoing clinical trials in extrapulmonary neuroendocrine carcinomas (epNECs), including DLL3-targeted therapies like T-cell engagers and antibody-drug conjugates. He discusses recent efficacy and safety data from several studies and considers where DLL3 may fit into the evolving treatment paradigm, as well as its potential role in guiding future therapeutic decisions.
Transcript
This video transcript has not been proofread or edited and may contain errors.
Hey everyone, I'm Uday Grewal, a GI and neuroendocrine medical oncologist at the Winship Cancer Institute of Emory University in Atlanta, Georgia. I'll be talking about DLL-3 targeting agents, um, discussing T cell engagers and beyond. I'm going to start by saying that DLL 3 is a versatile target. It has already made a big splash in the small cell lung cancer space, and it is quickly becoming the superstar biomarker in the EP neck space as well. The great thing about DLL-3 is that there are various agents that are currently showing encouraging data, and they're all targeting DLL-3 in different ways by using different mechanisms of action, be it T cell engagers, be it antibody drug conjugates, be it CAR T cell therapy, or be it radioligand therapy. So this just really adds another layer of promise to DLL-3 as a biomarker. I want to reiterate that EP neck or extrapulmonary neuroendocrine carcinoma space has been rather static for a while, and we have, you know, for long known the heterogeneity and aggressive nature of EP necks, and we also appreciated that The current standard of care, if you will, is chemotherapy. The outcomes are rather sobering and especially in the second line space, the outcomes are really disappointing, and most of our patients succumb to this disease within a year of diagnosis. But what's really exciting is that about 80% of EP neck tumors express DLL-3, making it a viable target that can bring a lot of novel therapies to more and more of our patients. So let's talk about a BRIXtamig. A BRIXtamig is a T cell engager and has shown potent preclinical anti-tumor activity against DLL 3 positive cells in Xenograft models. We know that about 80% EP neck tumors will express DLL 3 and CD3 is present on T cells. This is a bispecific T cell engager that targets both CD3 and DLL3 and generates a cytolytic synapse that brings these activated T cells and neuroendocrine carcinoma cells together and results in immune-mediated tumor cell killing. In early phase data, Abrixamig showed promising anti-tumor activity with a 22% response rate in all comers, and we noted a particularly high overall response rate in DLL-3 high tumors, which is expression of 50% or greater compared to 3% in DLL-3 low tumors. Similarly, disease control rate was about 47% and was noted to be greater at about 67% and DLL 3 high compared. To 27% in DLL 3 low. Median duration of response similarly was more encouraging in DLL 3 high tumors. That's about 7.9 months compared to 2.8 months in DLL 3 low. There were no concerning signals when it comes to safety. There were incidents of cytokine release syndrome or CRS and ICANNs, but the majority of those were grade 1 or 2. So encouraging data for safety and efficacy. Finally led to um um other trials such as Darian 7, which is a phase one dose escalation expansion trial of first line of bricks to make in combination with standard of care chemotherapy, which is carboplatin and etoposide. As we know from various cancers that if there is a therapy that works well, especially a targeted therapy, you try to bring it to first line um to improve upon the efficacy and also make it available to more and more patients. And we saw some encouraging data from Darian 7 presented at ESMO 2026 wherein the safety was kind of expected knowing that this was a combination with chemotherapy. We had some expected toxicities in terms of chemotherapy related. Adverse events, but when you look at brixamid related adverse events, uh, grade 3 toxicity was noted in 18.2% patients, but none of the patients actually had a grade 3, cytokine release syndrome or ICANNS. So encouraging data for safety and efficacy, and there appears to be a signal that, um, chemotherapy may actually have synergistic activity with brixamic, which is a T cell engager. Um, looking at the efficacy data, an overall response rate of 77.3% was recorded, and this was seen in both DLL 3 high and DLL 3 low subgroups, about 87.5% in DLL 3 high. And 65% in DLL 3 low. Similarly, looking at median duration of response was very encouraging, 20, 12.5 months. Um, and there are still ongoing responses in both uh DLL 3 high as well as DL3 low cohorts. So encouraging data for safety and efficacy from the Darian 7 trial. Similarly, there are ongoing studies looking at other agents such as cocatamib, which is a DLL 3 CD3 albumin targeted tri-specific T cell engager. There's Um, um, interest in looking at glucatamiq as a monotherapy, as well as in combination with other agents, and there were some updated data presented at ASMO 2026, which shows an encouraging, uh, overall response rate of about 44% and 66%. disease control rate. There were really no dose limiting toxicities, but important to acknowledge that there were grade 3 or higher toxicity in about 29% patients and mostly grade 1 to 2 CRS and ICANs, but something that we are always worried about and something we're always looking for in patients being treated with T cell engagers such as Abrixamig and cocadamib. There's also ongoing clinical trial looking at Zosi pelitecan, which is a DLN-3 targeting ADC. This is a phase 1-2 trial with this ADC that has a two isomerase 1 inhibitor payload, and updated data were presented at both ENET's 2026 and NET's 2026. And an overall response rate of about 38% and disease control rate of 56%, some expected toxicities knowing that there is a cytotoxic payload. What's really interesting is that there is no correlation with A score in terms of DLL-3 expression. So it's, it's evident that the activity is not limited by the level of expression of DLL-3, which makes sense considering this is an antibody drug conjugate and not a T cell engager. There's also an ongoing phase 3 trial, DariaEC 1, that is looking at frontline combination of aprixamig with cytotoxic chemotherapy such as carboplatin and etoposide compared to carboplatin and etoposide alone, and the study has a primary endpoint of overall survival with a number of secondary endpoints such as progression-free survival, objective response rate, duration. Response and others. This is an exciting study and will likely um make a bricks to make a center of care therapy if this trial turns out to be positive, uh, which will then be used in combination with chemotherapy, uh, carboplatin and etoposide. Let's talk about a hypothetical case of a patient with uh extrapulmonary neuroendocrine carcinoma. To understand what's the current paradigm and where DLL 3 targeting therapies and other therapies might fit in the future, this is a 64-year-old patient with no significant comorbidities and independently functioning at diagnosis who has a new diagnosis of a metastatic extrapulmonary neuroendocrine carcinoma of small cell subtype noted to have high expression of DLL 3 greater than 50%. And has multifocal liver metastases, abdominal lymphadenopathy, and has a pancreatic primary. So how do we go about discussing current treatment options and where do we think that TLL 3 targeting agents and other agents might fit in the paradigm? So the current paradigm is that we discuss platinum-based chemotherapy, typically carboplatin and etoposide in front line, and then in second line we try to use other chemotherapy regimens. And in patients with um a platinum sensitive disease, we may consider a platinum rechallenge. We may consider immunotherapy with EP and nivolumab based on other studies such as um DART and NIPI neck, etc. um, or consider clinical trials. I do want to highlight that there are currently no FDA approved therapies for EP neck. So I consider clinical trials to be very much a part of standard of care in patients with EP neck. Finally, I want to show the ongoing paradigm shift in EPNC, which is very encouraging to see. And a year or two ago, I don't think anybody would have imagined that we would have such a robust pipeline of agents in this space. But things have really exploded in the last year or so. We have T cell engagers targeting DLL-3 and other targets. We have antibody drug conjugates targeting DLL-3 and other targets like SEZ-6, DLK-1, TROP 2 that are being studied in this space, and also other agents, immunotherapy and beyond, that are currently being investigated in frontline and second line and beyond. That are um open um across centers in the US and internationally that can be and should be considered for all of our patients at whatever line of therapy it is possible. I do want to take the opportunity to share my excitement uh around the multiple different mechanisms of action that um these agents that are currently in the pipeline are using to target the same target. For example, DLL 3. Um, we've seen that the benefit with T cell engagers is primarily in DLL 3 high subgroups, but that changes a little bit with combination with chemotherapy. So I'm assuming that as in the direction that we're moving currently, T cell engagers might come to frontline. But encouragingly we don't really seem to need a lot of DLL-3 expression for therapeutic efficacy of antibody drug conjugates which might open doors for sequencing and using multiple different agents that target DLL-3 successively in the same patient. So this is an exciting time, exciting era, and I encourage all of my colleagues to consider enrolling their patients on clinical trials either at their institution or beyond because it's really important for us to ensure that patients get access to these novel therapies that are bringing so much promise with them.